50 related articles for article (PubMed ID: 10386182)
1. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations.
Lovestone S; Davis DR; Webster MT; Kaech S; Brion JP; Matus A; Anderton BH
Biol Psychiatry; 1999 Apr; 45(8):995-1003. PubMed ID: 10386182
[TBL] [Abstract][Full Text] [Related]
2. The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.
Buchholz S; Zempel H
Alzheimers Dement; 2024 May; 20(5):3606-3628. PubMed ID: 38556838
[TBL] [Abstract][Full Text] [Related]
3. Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.
Wei HF; Anchipolovsky S; Vera R; Liang G; Chuang DM
Eur Rev Med Pharmacol Sci; 2022 Mar; 26(6):2201-2214. PubMed ID: 35363371
[TBL] [Abstract][Full Text] [Related]
4. The next step of neurogenesis in the context of Alzheimer's disease.
Moradi HR; Hajali V; Khaksar Z; Vafaee F; Forouzanfar F; Negah SS
Mol Biol Rep; 2021 Jul; 48(7):5647-5660. PubMed ID: 34232464
[TBL] [Abstract][Full Text] [Related]
5. Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments.
Sales TA; Prandi IG; Castro AA; Leal DHS; Cunha EFFD; Kuca K; Ramalho TC
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013856
[TBL] [Abstract][Full Text] [Related]
6. Inositol depletion, GSK3 inhibition and bipolar disorder.
Yu W; Greenberg ML
Future Neurol; 2016 May; 11(2):135-148. PubMed ID: 29339929
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease.
Fernandez-Martos CM; Atkinson RAK; Chuah MI; King AE; Vickers JC
Alzheimers Dement (N Y); 2017 Jan; 3(1):92-106. PubMed ID: 29067321
[TBL] [Abstract][Full Text] [Related]
8. A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts.
Dell'Osso L; Del Grande C; Gesi C; Carmassi C; Musetti L
Neuropsychiatr Dis Treat; 2016; 12():1687-703. PubMed ID: 27468233
[TBL] [Abstract][Full Text] [Related]
9. Lithium suppression of tau induces brain iron accumulation and neurodegeneration.
Lei P; Ayton S; Appukuttan AT; Moon S; Duce JA; Volitakis I; Cherny R; Wood SJ; Greenough M; Berger G; Pantelis C; McGorry P; Yung A; Finkelstein DI; Bush AI
Mol Psychiatry; 2017 Mar; 22(3):396-406. PubMed ID: 27400857
[TBL] [Abstract][Full Text] [Related]
10. Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.
Pachima YI; Zhou LY; Lei P; Gozes I
J Mol Neurosci; 2016 Feb; 58(2):145-52. PubMed ID: 26816082
[No Abstract] [Full Text] [Related]
11. Long-Term Lithium Treatment Increases cPLA₂ and iPLA₂ Activity in Cultured Cortical and Hippocampal Neurons.
De-Paula Vde J; Kerr DS; de Carvalho MP; Schaeffer EL; Talib LL; Gattaz WF; Forlenza OV
Molecules; 2015 Nov; 20(11):19878-85. PubMed ID: 26556322
[TBL] [Abstract][Full Text] [Related]
12. HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.
Kadri F; Pacifici M; Wilk A; Parker-Struckhoff A; Del Valle L; Hauser KF; Knapp PE; Parsons C; Jeansonne D; Lassak A; Peruzzi F
J Biol Chem; 2015 Dec; 290(52):30931-46. PubMed ID: 26534959
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
Forlenza OV; De-Paula VJ; Diniz BS
ACS Chem Neurosci; 2014 Jun; 5(6):443-50. PubMed ID: 24766396
[TBL] [Abstract][Full Text] [Related]
14. Lithium: the pharmacodynamic actions of the amazing ion.
Brown KM; Tracy DK
Ther Adv Psychopharmacol; 2013 Jun; 3(3):163-76. PubMed ID: 24167688
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.
King MK; Pardo M; Cheng Y; Downey K; Jope RS; Beurel E
Pharmacol Ther; 2014 Jan; 141(1):1-12. PubMed ID: 23916593
[TBL] [Abstract][Full Text] [Related]
16. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders.
Diniz BS; Machado-Vieira R; Forlenza OV
Neuropsychiatr Dis Treat; 2013; 9():493-500. PubMed ID: 23596350
[TBL] [Abstract][Full Text] [Related]
17. Modelling tauopathies in Drosophila: insights from the fruit fly.
Cowan CM; Sealey MA; Quraishe S; Targett MT; Marcellus K; Allan D; Mudher A
Int J Alzheimers Dis; 2011; 2011():598157. PubMed ID: 22254145
[TBL] [Abstract][Full Text] [Related]
18. Fleshing out the amyloid cascade hypothesis: the molecular biology of Alzheimer's disease.
Lovestone S
Dialogues Clin Neurosci; 2000 Jun; 2(2):101-10. PubMed ID: 22033981
[TBL] [Abstract][Full Text] [Related]
19. NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.
Ali YO; Ruan K; Zhai RG
Hum Mol Genet; 2012 Jan; 21(2):237-50. PubMed ID: 21965302
[TBL] [Abstract][Full Text] [Related]
20. GSK-3 in Neurodegenerative Diseases.
Lei P; Ayton S; Bush AI; Adlard PA
Int J Alzheimers Dis; 2011; 2011():189246. PubMed ID: 21629738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
